The application of pharmacogenetics holds great promise for individualized therapy.
However, it has little clinical reality at present, despite many claims. The main problem is that …

Antianginal drugs that exert their anti-ischaemic effects primarily by altering myocardial
metabolism have recently attracted attention. They have the potential to relieve symptoms in …

ABSTRACT Perhexiline, 2‐(2, 2‐dicyclohexylethyl) piperidine, was originally developed as
an anti‐anginal drug in the 1970s. Despite its success, its use diminished due to the …

Nitric oxide (NO) is a physiologically important modulator of both vasomotor tone and
platelet aggregability. These effects of NO are predominantly mediated by cyclic guanosine …

OBJECTIVES The study examined possible clinical determinants of platelet resistance to
nitric oxide (NO) donors in patients with stable angina pectoris (SAP) and acute coronary …

Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy
in the management of angina pectoris. However, hepatic and neurological adverse effects …

Aims To examine whether the prophylactic antianginal agent perhexiline potentiates platelet
responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute …

Introduction Human epidermal growth factor receptor HER3 has been implicated in
promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of …

The prophylactic anti-anginal agent, perhexiline, may also be effective in acute coronary
syndromes and advanced aortic valvular stenosis, conditions associated with enhanced …

Approaches to the pharmacotherapy of angina pectoris have previously centred on the
concept that a transient imbalance between myocardial oxygen “demand” and supply within …